merck post impress support strong keytruda
vaccin sale
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jul
estim jun
price data jul
rate updat jul
currenc amount express
methodolog valu compani
merck report strong second-quart result ahead
consensu expect expect slightli rais
fair valu estim base out-performance
continu view merck modestli under-valued
market fulli appreci compani immuno-
oncolog drug keytruda especi earlier line
therapi continu success data keytruda
potenti reinforc strong price power
drug merck strong posit immuno-
oncolog help reinforc compani wide moat
total sale increas oper quarter
driven keytruda vaccin well declin gener
pressur older drug expect continu strong
growth next three year merck annual
sever major patent loss older drug face
major patent loss potenti patent
loss diabet drug januvia gener pressur
like weigh growth sever year keytruda
remain earli part life-cycle signific
potenti market gain alreadi approv indic
well like new indic expect keytruda
posit well earlier-stag cancer recent
posit data neoadjuv triple-neg breast cancer
support keytruda use earlier line therapi
addit growth keytruda like
amplifi impact bottom line project higher
margin drug rel overal compani base
strong price power drug outsid keytruda
vaccin busi continu post excel growth
demand china help drive sale expect
human papillomaviru vaccin gardasil particularli well
posit growth intern market
merck make progress pipelin front
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
merck make pharmaceut product treat sever condit
number therapeut area includ cardiovascular diseas asthma
cancer infect within cancer firm immuno-oncolog platform
grow major contributor overal sale compani also
substanti vaccin busi treatment prevent hepat
pediatr diseas well hpv shingl addit merck sell
anim health-rel drug geograph perspect close
compani sale gener unit state
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
encourag data come oncolog platform
believ next major develop merck pipelin
keytruda adjuvant/neoadjuv use
especi focus lung cancer aggreg project
lung adjuvant/neoadjuv market expand
potenti close billion annual sale
probability-weight ad almost billion
project late-stag metastat set estim
probabl success early-treat set
base earli clinic data strength drug
late-stag set view merck roch best
posit adjuv set due first-mov
advantag upcom clinic data
complet review outlook immuno-oncolog
drug earlier line usag pleas see recent
report immuno-oncolog drug adjuv lung
frontier strengthen moat overview
merck pipelin asset pleas see healthcar
secur
innov counter price gener
headwind acceler
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
equival
net properti plant equip
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
